马来酸依那普利叶酸片的药理学与临床评价

Pharmacology and clinical evaluation of enalapril maleate and folic acid tablet

依那普利叶酸片是第一个批准用于治疗伴同型半胱氨酸升高的原发性高血压的药物,于2008年3月获得SFDA批准上市,其组方及配比获得国家发明专利。高血压与高同型半胱氨酸可能是导致我国脑卒中高发的最重要的两个危险因素。依那普利叶酸片较单用降压药进一步降低脑卒中风险25%－37%。文中综述了该药的创新思路、药动学、药效学、临床研究与不良反应。

Enalapril maleate and folic acid tablet is the first novel combination drug approved by SFDA in 2008.Its indication is essential hypertension complicated with homocysteinemia.Hypertension and homocysteinemia are two critical independent risk factors for stroke.Enalapril maleate and folic acid tablets reduced the risk of stroke incidence by 25%~37% more than the anti-hypertensive drug alone does.In this article,we introduced the innovation strategy of the enalapril maleate and folic acid tablet,and its pharmacokinetics,pharmacodynamics,clinical trial findings and adverse reactions.